The vascular contribution to Alzheimer's disease

Robin Altman, John C Rutledge

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

AD (Alzheimer's disease) is a progressive neurodegenerative disease of unknown origin. Despite questions as to the underlying cause(s) of this disease, shared risk factors for both AD and atherosclerotic cardiovascular disease indicate that vascular mechanisms may critically contribute to the development and progression of both AD and atherosclerosis. An increased risk of developing AD is linked to the presence of the apoE4 (apolipoprotein E4) allele, which is also strongly associated with increased risk of developing atherosclerotic cardiovascular disease. Recent studies also indicate that cardiovascular risk factors, including elevated blood cholesterol and triacylglycerol (triglyceride), increase the likelihood of AD and vascular dementia. Lipids and lipoproteins in the circulation interact intimately with the cerebrovasculature, and may have important effects on its constituent brain microvascular endothelial cells and the adjoining astrocytes, which are components of the neurovascular unit. The present review will examine the potential mechanisms for understanding the contributions of vascular factors, including lipids, lipoproteins and cerebrovascular Aβ (amyloid β), to AD, and suggest therapeutic strategies for the attenuation of this devastating disease process. Specifically, we will focus on the actions of apoE, TGRLs (triacylglycerol-rich lipoproteins) and TGRL lipolysis products on injury of the neurovascular unit and increases in blood-brain barrier permeability.

Original languageEnglish (US)
Pages (from-to)407-421
Number of pages15
JournalClinical Science
Volume119
Issue number10
DOIs
StatePublished - Nov 2010

Fingerprint

Blood Vessels
Alzheimer Disease
Lipoproteins
Triglycerides
Cardiovascular Diseases
Apolipoprotein E4
Lipids
Vascular Dementia
Lipolysis
Apolipoproteins E
Hypercholesterolemia
Blood-Brain Barrier
Amyloid
Astrocytes
Neurodegenerative Diseases
Permeability
Atherosclerosis
Endothelial Cells
Alleles
Wounds and Injuries

Keywords

  • Alzheimer's disease
  • Apolipoprotein E (apoe)
  • Astrocyte
  • Endothelial cell
  • Lipoprotein
  • Triacylglycerol-rich lipoprotein (tgrl)
  • Vascular system

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The vascular contribution to Alzheimer's disease. / Altman, Robin; Rutledge, John C.

In: Clinical Science, Vol. 119, No. 10, 11.2010, p. 407-421.

Research output: Contribution to journalArticle

Altman, Robin ; Rutledge, John C. / The vascular contribution to Alzheimer's disease. In: Clinical Science. 2010 ; Vol. 119, No. 10. pp. 407-421.
@article{ca8ba293e1554a4eac7e9dcd0ada6b7e,
title = "The vascular contribution to Alzheimer's disease",
abstract = "AD (Alzheimer's disease) is a progressive neurodegenerative disease of unknown origin. Despite questions as to the underlying cause(s) of this disease, shared risk factors for both AD and atherosclerotic cardiovascular disease indicate that vascular mechanisms may critically contribute to the development and progression of both AD and atherosclerosis. An increased risk of developing AD is linked to the presence of the apoE4 (apolipoprotein E4) allele, which is also strongly associated with increased risk of developing atherosclerotic cardiovascular disease. Recent studies also indicate that cardiovascular risk factors, including elevated blood cholesterol and triacylglycerol (triglyceride), increase the likelihood of AD and vascular dementia. Lipids and lipoproteins in the circulation interact intimately with the cerebrovasculature, and may have important effects on its constituent brain microvascular endothelial cells and the adjoining astrocytes, which are components of the neurovascular unit. The present review will examine the potential mechanisms for understanding the contributions of vascular factors, including lipids, lipoproteins and cerebrovascular Aβ (amyloid β), to AD, and suggest therapeutic strategies for the attenuation of this devastating disease process. Specifically, we will focus on the actions of apoE, TGRLs (triacylglycerol-rich lipoproteins) and TGRL lipolysis products on injury of the neurovascular unit and increases in blood-brain barrier permeability.",
keywords = "Alzheimer's disease, Apolipoprotein E (apoe), Astrocyte, Endothelial cell, Lipoprotein, Triacylglycerol-rich lipoprotein (tgrl), Vascular system",
author = "Robin Altman and Rutledge, {John C}",
year = "2010",
month = "11",
doi = "10.1042/CS20100094",
language = "English (US)",
volume = "119",
pages = "407--421",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "10",

}

TY - JOUR

T1 - The vascular contribution to Alzheimer's disease

AU - Altman, Robin

AU - Rutledge, John C

PY - 2010/11

Y1 - 2010/11

N2 - AD (Alzheimer's disease) is a progressive neurodegenerative disease of unknown origin. Despite questions as to the underlying cause(s) of this disease, shared risk factors for both AD and atherosclerotic cardiovascular disease indicate that vascular mechanisms may critically contribute to the development and progression of both AD and atherosclerosis. An increased risk of developing AD is linked to the presence of the apoE4 (apolipoprotein E4) allele, which is also strongly associated with increased risk of developing atherosclerotic cardiovascular disease. Recent studies also indicate that cardiovascular risk factors, including elevated blood cholesterol and triacylglycerol (triglyceride), increase the likelihood of AD and vascular dementia. Lipids and lipoproteins in the circulation interact intimately with the cerebrovasculature, and may have important effects on its constituent brain microvascular endothelial cells and the adjoining astrocytes, which are components of the neurovascular unit. The present review will examine the potential mechanisms for understanding the contributions of vascular factors, including lipids, lipoproteins and cerebrovascular Aβ (amyloid β), to AD, and suggest therapeutic strategies for the attenuation of this devastating disease process. Specifically, we will focus on the actions of apoE, TGRLs (triacylglycerol-rich lipoproteins) and TGRL lipolysis products on injury of the neurovascular unit and increases in blood-brain barrier permeability.

AB - AD (Alzheimer's disease) is a progressive neurodegenerative disease of unknown origin. Despite questions as to the underlying cause(s) of this disease, shared risk factors for both AD and atherosclerotic cardiovascular disease indicate that vascular mechanisms may critically contribute to the development and progression of both AD and atherosclerosis. An increased risk of developing AD is linked to the presence of the apoE4 (apolipoprotein E4) allele, which is also strongly associated with increased risk of developing atherosclerotic cardiovascular disease. Recent studies also indicate that cardiovascular risk factors, including elevated blood cholesterol and triacylglycerol (triglyceride), increase the likelihood of AD and vascular dementia. Lipids and lipoproteins in the circulation interact intimately with the cerebrovasculature, and may have important effects on its constituent brain microvascular endothelial cells and the adjoining astrocytes, which are components of the neurovascular unit. The present review will examine the potential mechanisms for understanding the contributions of vascular factors, including lipids, lipoproteins and cerebrovascular Aβ (amyloid β), to AD, and suggest therapeutic strategies for the attenuation of this devastating disease process. Specifically, we will focus on the actions of apoE, TGRLs (triacylglycerol-rich lipoproteins) and TGRL lipolysis products on injury of the neurovascular unit and increases in blood-brain barrier permeability.

KW - Alzheimer's disease

KW - Apolipoprotein E (apoe)

KW - Astrocyte

KW - Endothelial cell

KW - Lipoprotein

KW - Triacylglycerol-rich lipoprotein (tgrl)

KW - Vascular system

UR - http://www.scopus.com/inward/record.url?scp=77956410028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956410028&partnerID=8YFLogxK

U2 - 10.1042/CS20100094

DO - 10.1042/CS20100094

M3 - Article

C2 - 20684749

AN - SCOPUS:77956410028

VL - 119

SP - 407

EP - 421

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 10

ER -